MAPK1 and lung carcinoma: Exogenous lysoPC inhibited lung cancer cell proliferation by promoting ACSL5, leading to the disorder of FA degradation and metabolism, compromise of mitochondrial morphology and functions and reprogramming of ACSL5/PI3K/ERK‐regulated TAG metabolism.